Biotech Connection Singapore

Introduction to Translational Medicine

Thursday 10 May 2018, 6:30 PM – 7:30 PM

Thursday, May 10, 2018
6:30 PM – 7:30 PM

SingHealth Academia, 20 College Road, L1-S1

Singapore 169856

Translational medicine is central to the goal of converting basic discoveries to diagnostic and therapeutic tools that can be harnessed to treat disease and improve human health. The field of translational medicine is multidisciplinary, encompassing molecular medicine, intellectual property, financing, regulation, preclinical and clinical trial studies, among others. Join us for our first event of a series on translational medicine in collaboration with Eureka Institute of Translational Medicine.

  1. Highlight the key steps from basic research findings to clinical studies
  2. Discuss designing and managing clinical trials, including data management and interpretation
  3. Explore the intersection of interests between key stakeholders, such as patients, clinicians, scientists, funders and regulators.


6:00-6:30pm Registration

6:30-6:40pm Welcome address by Eureka Institute and BCS

6:40-7:00pm Lecture by Prof Salvatore Albani: “Principles of translational medicine and is your technology marketable”

7:00-7:30pm Panel discussion and Q&A

7:30-8:00pm Refreshments and networking


Salvatore Albani, MD, PhD

Director, Translational Immunology Institute
President, Eureka Institute for Translational Medicine

Professor Albani is an internationally renowned rheumatologist and immunologist. His fundamental research interest is in understanding human immunity and contributing the knowledge to therapeutic and diagnostic advancements. He developed several innovative approaches in the area of induction and maintenance of immune tolerance in humans, being responsible for the whole translational process from idea to conclusion of Phase II clinical trial in autoimmune inflammatory diseases, which have a large impact on society and individuals. This translational research itinerary has been the original backbone of his career, as witnessed by a rich publication trail (among others Nature Medicine, Lancet, JCI, PNAS, Nature Rheumatology, A&R, ARD, etc) and by approximately 100 patents, disclosures and applications.

Mr. Xiangliang Lin

President, Esco Healthcare

Xiangliang (XL) Lin is the Founder & President of Esco Healthcare, a division of Esco Group of Companies. Esco boasts its strength of multiple manufacturing sites across the globe. XL also designed and oversaw the engineering, manufacturing and validation of the company’s first cGMP-compliant isolators, downflow booths, bioreactors, and clean air & containment technology.

Esco transitioned from tools provider to on-site process development and with its developed technologies, Esco Aster was formed in 2018. Today, Esco Aster is the leading independent Contract Development and Manufacturing Organization (CDMO).

XL Lin graduated with a degree in Bachelor of Sciences from University of Sydney and has plans to further his studies.

Stuart Cook, MBBS, MRCP, PhD

Professor, Imperial College London
Professor, Duke-NUS
Director and Co-Founder, Enleofen

Dr. Stuart Cook grew up in Kenya, went to high school at St Edward’s, Oxford and studied medicine at St Bartholomew’s Medical School, London. He did a PhD at the National Heart and Lung Institute, UK and a Postdoctoral Fellowship at Harvard. He trained in cardiology and sub-specialized in cardiac MRI. He is Professor at Imperial College, London and Duke-National University of Singapore (Duke-NUS). He is a cardiologist at the National Heart Centre Singapore where he oversees the clinical MRI service. He is the Director of the National Heart Research Institute Singapore and Program Director of the CVMD program at Duke-NUS. He is co-founder of Enleofen, a biotechnology company developing therapies for the treatment of fibrotic diseases.

Co-organized by

The EUREKA Institute for Translational Medicine was established in 2008 by leaders in the field and incorporated as a not-for-profit organization. The birth of Eureka arises from the realization that the itinerary from molecular to clinical medicine requires a seamless trajectory to insure that talent, ideas, and potential cures are captured. Eureka Singapore aims to develop a community of Translational Medicine professionals, in Asia-Pacific, to advance the application of biomedical innovation for the tangible benefit of patients and society as a whole.


%d bloggers like this: